Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-[(Cyclohexylamino)carbonyl]glycine is a small molecule experimental compound with the molecular formula C9H16N2O3 and a molecular weight of approximately 200.23 g/mol. It is structurally characterized as an alpha amino acid derivative bearing a carbamoyl group at its terminal nitrogen atom, specifically substituted with a cyclohexyl group. The compound has been identified as an inhibitor of bifunctional epoxide hydrolase 2 (also known as soluble epoxide hydrolase or EPHX2), suggesting potential utility in modulating pathways involving this enzyme. There are no approved indications or clinical trial phases reported for this molecule, and it remains classified as experimental[1][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-[(cyclohexylamino)carbonyl]glycine.